Is Subcutaneous Bortezomib Ready for Prime Time? Sagar Lonial CLINICAL TRIAL REPORT 16 February 2011 Pages: 73 - 74
Chronic Myelogenous Leukemia: Monitoring Response to Therapy Susan BranfordJodi Prime ReviewPaper 01 March 2011 Pages: 75 - 81
In Search of CML Stem Cells’ Deadly Weakness Francesca PellicanoAmy SinclairTessa L. Holyoake ReviewPaper 04 March 2011 Pages: 82 - 87
Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy Deborah L. WhiteTimothy P. Hughes ReviewPaper 30 March 2011 Pages: 88 - 95
New Drugs for Chronic Myelogenous Leukemia Fabio P. S. SantosAlfonso Quintás-Cardama ReviewPaper 16 February 2011 Pages: 96 - 103
Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients Shaji Kumar ReviewPaper 11 March 2011 Pages: 104 - 112
Treatment of Newly Diagnosed Myeloma in Patients not Eligible for Transplantation M. Victoria MateosJesús San-Miguel ReviewPaper 24 February 2011 Pages: 113 - 119
Updates in Cytogenetics and Molecular Markers in MDS Ramon V. TiuValeria VisconteJaroslaw P. Maciejewski ReviewPaper 22 February 2011 Pages: 126 - 135
The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate David P. Steensma ReviewPaper 05 March 2011 Pages: 136 - 144
Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence Rami S. KomrokjiMikkael A. SekeresAlan F. List ReviewPaper 26 March 2011 Pages: 145 - 153